Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Adjuvant chemotherapy improves survival in early-stage ovarian cancer

15.01.2003


Results from two large European studies suggest that adjuvant chemotherapy immediately after surgery for early-stage ovarian cancer can increase some patients’ chances of both overall and recurrence-free survival. The findings are reported in three articles in the January 15 issue of the Journal of the National Cancer Institute.



As many as 50% of patients with early-stage ovarian cancer relapse after surgery, and these subsequent tumor recurrences are often resistant to treatment. Adjuvant chemotherapy has been used to prevent recurrence; however, definitive data are lacking on the effectiveness of adjuvant therapy, and there is no information available about which patients may benefit the most. In addition, previous trials have been too small to provide clear answers.

In the early 1990s, two large randomized clinical trials were initiated to compare survival between patients treated with adjuvant chemotherapy immediately after surgery for early-stage ovarian cancer and patients who received no additional treatments until clinically indicated.


In the Adjuvant ChemoTherapy in Ovarian Neoplasm (ACTION) trial, a team of researchers from the European Organisation for Research and Treatment of Cancer (EORTC) randomly assigned 448 patients from across Europe to either adjuvant platinum-based chemotherapy or observation following surgery. This trial also examined the impact of completeness of surgical staging on survival. One-third of the patents received optimal surgical staging for their cancers. This meant that clinicians performed all the requirements to determine the extent of the disease, or its stage. The remaining two-thirds of patients received nonoptimal surgical staging.

At 5 years, there was no statistically significant difference in overall survival between patients who were treated with adjuvant chemotherapy and patients who were in the observation group. However, recurrence-free survival was statistically significantly improved, with 76% of patients treated with adjuvant chemotherapy surviving without a recurrence, compared with 68% of patients in the observation arm.

Moreover, the authors found that among patients who did not receive adjuvant chemotherapy, optimal staging was associated with a statistically significant improvement in overall and recurrence-free survival. In contrast, optimal staging was not associated with any survival benefit in patients who received adjuvant chemotherapy. Adjuvant chemotherapy appeared to only benefit patients whose cancers were not optimally staged.

"This finding suggests that adjuvant chemotherapy in early-stage ovarian cancer may work predominantly by affecting small-volume or microscopic tumor implants or metastases that remain unnoticed at the time of surgical staging," the authors write. They add that the observed benefit of adjuvant chemotherapy primarily in nonoptimally staged patients suggests a benefit of adjuvant chemotherapy predominantly in patients with unrecognized residual disease.

In a second trial, the International Collaborative Ovarian Neoplasm (ICON1) study, collaborators randomly assigned 477 patients to receive either adjuvant chemotherapy immediately after surgery for early-stage ovarian cancer or no immediate adjuvant chemotherapy. (Information on the completeness of surgical staging was not collected in this trial.)

At 5 years, women who received adjuvant chemotherapy had a 9% greater overall survival and an 11% greater recurrence-free survival than women who did not receive immediate adjuvant therapy.

In a separate paper, researchers reported findings from a combined analysis of the two trials. Similar to the ICON1 trial, the combined analysis found that 5-year overall survival was 8% greater in the adjuvant chemotherapy arm than in the observation arm. The analysis also found that 5-year recurrence-free survival was 11% better in the adjuvant chemotherapy arm than in the observation arm.

In an accompanying editorial, Robert C. Young, M.D., of the Fox Chase Cancer Center in Philadelphia, says that the trials add important information on adjuvant chemotherapy but do not address which patients can be spared unnecessary adjuvant chemotherapy.

He recommends that future trials focus on identifying patients who do not require additional therapy while also seeking to improve therapy in patients who do. "Selecting only high-risk patients for additional treatment can narrow the use of chemotherapy, and this approach should be used until such time as a randomized trial can demonstrate that good prognosis, early-stage patients benefit from such therapy," he writes.


Contact: Dr. J. Baptist Trimbos, Leiden University Medical Center, Netherlands, 31-71-526-2845, J.B.M.Z.Trimbos@lumc.nl

Dr. David Guthrie, Derbyshire Royal Infirmary, 44-122-852-3444, DGJCGuthrie@aol.com

Editorial: Karen Carter Mallet, Fox Chase Cancer Center, 215-728-2700; fax: 215-728-2594, k_carter@fccc.edu

International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy in Ovarian Neoplasm Trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95:105–112.

Trimbos J, Vergote I, Bolis G, Vermorken J, Mangioni C, Madronal C, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer–Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 2003;95:113–25.

International Collaborative Ovarian Neoplasm Trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003;95:125–32.

Editorial: Young R. Early-stage ovarian cancer: To treat or not to treat. J Natl Cancer Inst 2003;95:94–5.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Linda Wang | EurekAlert!
Further information:
http://jncicancerspectrum.oupjournals.org/

More articles from Health and Medicine:

nachricht TSRI researchers develop new method to 'fingerprint' HIV
29.03.2017 | Scripps Research Institute

nachricht Periodic ventilation keeps more pollen out than tilted-open windows
29.03.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Challenging European Research Project to Develop New Tiny Microscopes

The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.

To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Researchers shoot for success with simulations of laser pulse-material interactions

29.03.2017 | Materials Sciences

Igniting a solar flare in the corona with lower-atmosphere kindling

29.03.2017 | Physics and Astronomy

As sea level rises, much of Honolulu and Waikiki vulnerable to groundwater inundation

29.03.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>